QT Imaging Holdings (QTI) Investor presentation summary

Mission and value proposition

• Aims to transform breast health with a scalable, safe, high-resolution 3D imaging platform for dense breast diagnostics and precision oncology.

• Offers a pain-free, radiation-free, and operator-independent solution validated by FDA clearance.

• Provides accurate diagnosis in dense breasts, reducing unnecessary biopsies and patient anxiety.

• Delivers benefits for patients, clinicians, and administrators, including lower recall rates, reduced labor costs, and faster investment recovery.

Technology and clinical validation

• Utilizes a proprietary, FDA-cleared, 3D quantitative imaging modality combining transmission and reflection ultrasound for high-resolution, MRI-like images.

• Clinical studies at Mayo Clinic and Sunnybrook Cancer Center show strong agreement with MRI for both screening and treatment monitoring.

• Multi-site reproducibility studies confirm high precision and operator independence, outperforming MRI biomarkers in consistency.

• Ongoing and planned studies at leading institutions support broader adoption.

Market opportunity and growth drivers

• Targets a $6B global breast imaging market, with a $1B opportunity in SaaS biomarkers and a projected $200M+ revenue at 10% SAM penetration by 2030.

• Positioned at the intersection of AI-enabled radiology and precision oncology, leveraging regulatory, AI, and oncology tailwinds.

• Regulatory approvals in the US, Saudi Arabia, UAE, and Israel, with CE Mark targeted for 2027.

• NIH awarded $18M for development and validation of dense breast imaging.